论文部分内容阅读
目的:观察GEMOX方案联合干扰素治疗晚期原发性肝癌的近期疗效和不良反应。方法:32例晚期原发性肝癌均采用GEMOX方案联合干扰素进行化疗及生物治疗,吉西他滨1000 mg/m2,静脉滴注,第1,8天;奥沙利铂100 mg/m2,静脉滴注,第1,8天。21天为一个周期。干扰素600 MIU ih QOD,连用6周。结果:所有患者均完成>2个周期的GEMOX方案联合干扰素治疗,疾病控制率为65.63%,部分缓解率15.63%,疾病稳定率50%。主要不良反应是骨髓抑制和神经毒性,经治疗均恢复。结论:GEMOX方案联合干扰素治疗晚期原发性肝癌,近期疗效确切,毒副作用可耐受,远期疗效有待观察。
Objective: To observe the short-term efficacy and adverse reactions of GEMOX combined with interferon in the treatment of advanced primary liver cancer. METHODS: Thirty-two patients with advanced primary liver cancer were treated with GEMOX regimen combined with interferon for chemotherapy and biotherapy, gemcitabine 1000 mg / m2, intravenous drip, on day 1,8, oxaliplatin 100 mg / m2, intravenous drip Day 1,8. 21 days for a cycle. Interferon 600 MIU ih QOD, used in combination for 6 weeks. Results: All patients completed> 2 cycles of GEMOX combined with interferon treatment. The disease control rate was 65.63%, partial response rate was 15.63%, and disease stability rate was 50%. The main adverse reactions were myelosuppression and neurotoxicity, which were recovered after treatment. Conclusion: GEMOX combined with interferon in the treatment of advanced primary liver cancer has definite curative effect in the near future and tolerable side effects. The long-term curative effect remains to be seen.